Govt will protect interests of drug industry: Scindia

Image
Press Trust of India New Delhi
Last Updated : Jan 20 2013 | 8:04 PM IST

Amid concerns expressed by the Indian industry, the government today said in Parliament that it will protect the interest of the domestic drug industry while finalising the free trade pact with European Union.

"Public health concerns and interests of domestic drug industry will guide our negotiating position," Minister of State for Commerce and Industry Jyotiraditya Scindia said in a written reply to Lok Sabha.

The two sides have already completed 12 round of talks since June 2007 for the Bilateral Trade and Investment Agreement (BTIA) for opening up commerce in goods, services and investment, he said.

The talks had hit roadblocks as there was pressure from EU members that social issues like environment, labour standards and TRIPS plus should be covered in the agreement. However, India has been resisting these efforts.

"India has clarified to the EU that it cannot accept provisions in the agreement, which are beyond TRIPS (Trade Related aspects of Intellectual Property Rights) and domestic law," he said.

The TRIPS agreement was signed as part of the multilateral trade pact of the WTO during the Uruguay Round in 1994. Under this, developing countries including India made several important changes in their domestic IPR regime to make it more stringent.

However, India is strongly opposing going beyond TRIPS in any bilateral free-trade pact, as the move could render a lot of genuine products like generic medicines and software illegal. It can restrict the ability of Indian pharmaceutical firms to produce and export generic or off-patent drugs.

Indian pharma industry and several NGOs have been strongly opposing the proposed bilateral pact on the grounds that it will require India to make TRIPS-plus commitment.

The EU and other developed countries believe a TRIPS-plus pact is a must for tackling the problem of counterfeit drugs.

The EU is India’s largest trading partner. The bilateral trade in 2009-10 aggregated to $75 billion. Both the sides are expected to conclude the negotiations by the end of this year.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 14 2011 | 3:37 PM IST

Next Story